



POLYPILL

CONSIDERATIONS

1. Less than 50% of hypertensive patients are managed to goal on one medication.
2. 32 million people are taking 3 or more medications per day.
3. Every increase in dosing frequency reduces adherence by 22%.
4. Adherence to hypertensive therapies in U.S. is 51%.
5. Of patients on 5 or more medications, 59% take them incorrectly.
6. PolyPill is a single daily dose. Each increase in daily dose *reduces adherence by 22%*.
7. PolyPill therapy is individualized.
8. Reduced side effects via synergy of reduced dose.
9. Addresses patient compliance, adherence and persistence.
10. Incorporates drugs with many years documented safety and efficacy.
11. Cost savings of as much as \$400.00 per year (based on rxusa.com).

